In short
This article discusses the use of D-Biotin, a component of the multivitamin drug Cernevit, in clinical trials for patients with cardiogenic shock. The study aims to explore the effects of this multivitamin solution on patients undergoing extracorporeal membrane oxygenation (ECMO) treatment. We'll examine the trial's objectives, eligibility criteria, and potential outcomes for patients with severe heart conditions.
At a glance
- Study Drug
- Cernevit (multivitamin solution containing D-Biotin)
- Medical Condition
- Cardiogenic Shock
- Primary Objective
- Assess efficacy of Levosimendan in improving cardiac output and pulsatile flow
- Primary Outcome
- Change in left ventricular outflow tract velocity time integral
- Key Inclusion Criteria
- Age ≥ 18 years, undergoing ECMO for cardiogenic shock or refractory cardiac arrest
- Key Exclusion Criteria
- Coma with fixed pupil dilation, mechanical cause of shock, onset of shock > 12 hours before screening
- Secondary Outcomes
- Change in pulse pressure, ECMO weaning failure, mortality at 28 days, urinary output, central venous saturation
What is D-Biotin?
D-Biotin, also known simply as biotin, is a B-complex vitamin (vitamin B7) that plays a crucial role in various bodily functions. It is an essential nutrient that helps your body convert food into energy and supports the health of your hair, skin, and nails. In the medical context, D-Biotin is often used as part of a multivitamin formulation for patients with specific nutritional needs.
Uses and Benefits
While the primary focus of the clinical trial mentioned in the source document is not on D-Biotin specifically, it is included as part of a multivitamin solution called Cernevit. This medication is being used as a placebo in a study involving patients with cardiogenic shock, a serious condition where the heart cannot pump enough blood to meet the body's needs.
In general, D-Biotin and other vitamins in such formulations can be beneficial for:
- Supporting overall nutritional status in critically ill patients
- Helping the body convert food into energy
- Maintaining healthy hair, skin, and nails
- Supporting metabolism of fats and carbohydrates
Administration
According to the information provided, the medication containing D-Biotin (Cernevit) is administered as a solution for injection or infusion. This means it is given directly into the bloodstream, usually in a hospital or clinical setting. The exact dosage and frequency of administration would be determined by healthcare professionals based on the patient's specific needs.
Other Components in the Medication
It's important to note that D-Biotin is just one of several vitamins and nutrients included in the Cernevit formulation. Other components include:
- Retinol Palmitate (a form of Vitamin A)
- Ascorbic Acid (Vitamin C)
- Colecalciferol (Vitamin D3)
- Cyanocobalamin (Vitamin B12)
- Dexpanthenol (a form of Vitamin B5)
- Folic Acid (Vitamin B9)
- Nicotinamide (a form of Vitamin B3)
- Pyridoxine Hydrochloride (Vitamin B6)
- Riboflavin Sodium Phosphate (a form of Vitamin B2)
- DL-Alpha-Tocopherol (Vitamin E)
- Cocarboxylase Tetrahydrate (a form of Vitamin B1)
This combination of vitamins is designed to provide comprehensive nutritional support for patients who may have difficulty obtaining these nutrients through their regular diet.
Important Considerations
While D-Biotin and the other vitamins in this formulation are generally considered safe, it's crucial to remember that:
- This medication should only be administered under medical supervision.
- It's typically used in hospital settings for patients with specific medical conditions or nutritional needs.
- As with any medical treatment, there may be potential side effects or interactions with other medications.
- The use of this vitamin formulation as a placebo in the mentioned clinical trial does not imply that it treats cardiogenic shock directly.
Always consult with your healthcare provider for personalized medical advice and before starting or changing any treatment regimen.